Aligos Therapeutics: Strong Buy Rating Backed by Promising Liver Disease Treatments and Strategic Positioning
Patrick Trucchio from H.C. Wainwright reiterated a Buy rating for Aligos Therapeutics, with a $50 price target. The company's focus on chronic HBV and MASH shows promising results, with lead drug pevifoscorvir sodium potentially replacing standard HBV treatments. ALG-055009 has shown strong efficacy in Phase 2 trials. Aligos has a solid cash position and upcoming milestones, supporting its leadership in liver disease innovation.
In a report released today, Patrick Trucchio from H.C. Wainwright reiterated a Buy rating on Aligos Therapeutics, with a price target of $50.00.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Patrick Trucchio has given his Buy rating due to a combination of factors that highlight Aligos Therapeutics’ strong position in the field of liver disease treatment. The company’s focus on chronic hepatitis B virus (HBV) and metabolic dysfunction-associated steatohepatitis (MASH) has shown promising results, with their lead programs demonstrating significant potential. The management’s confidence and data-driven approach, as presented during the non-deal roadshow, underscore the company’s strategic positioning and execution capabilities.
Aligos’ lead drug, pevifoscorvir sodium, is positioned to potentially replace standard treatments for chronic HBV due to its rapid and durable viral clearance and high barrier to resistance. Additionally, ALG-055009 has shown strong efficacy and safety in Phase 2 trials, attracting interest for potential partnerships. With a solid cash position projected to last into the third quarter of 2026 and multiple upcoming milestones, Trucchio believes Aligos is well-positioned to maintain its leadership in liver disease innovation, justifying the Buy rating and a price target of $50.
